UNSPSC 51272304: Etomidate hydrochloride

This classification denotes an anesthetic agent with the molecular formula C14H16N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZUM3W5027S. European Medicines Agency schedules etomidate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02046MIG. Most nations, for tariff and trade purposes, schedule etomidate hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ETOMIDATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCOC(=O)C1CNCN1[C@H](C)C2CCCCC2.CL.

UNSPSC 51272304 Etomidate hydrochloride is a Commodity code that nominally covers a specific intravenous anesthetic agent, but recent state and local procurement activity under this code shows little direct alignment with the product's abstract classification. The three recent opportunities posted between January and June 2026 involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative exploring direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). State and local issuing bodies tagging opportunities to this code span county health departments, state health and human services agencies, and multistate cooperative purchasing organizations. The actual purchasing activity visible in these solicitations centers on commodity pharmaceutical supply chains—acquiring bulk quantities of off-patent drugs, naloxone for community health and emergency response, and OTC products through established wholesaler networks rather than procurement of etomidate specifically.

Geographic activity appears concentrated in the Southeast (Florida) and Midwest (Minnesota, with Oregon participation through MMCAP), with Texas engaging in exploratory market research on prescription fulfillment models. Representative recent opportunities include Seminole County's IFB for 1,900 annual units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly delivery to Sanford, Florida (IFB 60459723LAS, due July 26, 2023), and MMCAP's RFP to establish multiple contracts for generic pharmaceuticals and OTC products across state and local facilities, with proposals due March 26, 2026. The Texas HHS RFI (HHS0017013, posted April 3, 2026) represents a preliminary information-gathering phase rather than a formal competitive bid, seeking vendor capabilities for direct contracting with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. No specific budget allocations, set-aside designations, or incumbent vendor information are disclosed in the available solicitation materials for this code.